DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort.
Adult
Biomarkers, Tumor
/ genetics
Cohort Studies
Colposcopy
DNA Methylation
Female
Humans
Mass Screening
/ methods
Middle Aged
Papillomaviridae
/ physiology
Papillomavirus Infections
/ diagnosis
Sensitivity and Specificity
Triage
/ methods
Uterine Cervical Neoplasms
/ diagnosis
Uterine Cervical Dysplasia
/ diagnosis
(pre)malignant cervical cancer
DNA methylation markers
cervical cancer screening
high-risk human papillomavirus (hrHPV)
triage test
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 02 2019
15 02 2019
Historique:
received:
12
04
2018
revised:
03
08
2018
accepted:
23
08
2018
pubmed:
28
9
2018
medline:
28
5
2019
entrez:
28
9
2018
Statut:
ppublish
Résumé
Objective triage strategies are required to prevent unnecessary referrals for colposcopy in population-based screening programs using primary high-risk human papillomavirus (hrHPV) testing. We have identified several DNA methylation markers with high sensitivity and specificity for detection of high-grade cervical intraepithelial neoplasia or worse (CIN2+) in women referred for colposcopy. Our study assessed diagnostic potential of these methylation markers in a hrHPV-positive screening cohort. All six markers (JAM3, EPB41L3, C13orf18, ANKRD18CP, ZSCAN1 and SOX1) showed similar association across histology in the hrHPV-positive cohort when compared to the Dutch cohort (each p > 0.15). Sensitivity for CIN2+ was higher using methylation panel C13orf18/EPB41L3/JAM3 compared to the other 2 panels (80% vs. 60% (ANKRD18CP/C13orf18/JAM3) and 63% (SOX1/ZSCAN1), p = 0.01). For CIN3+ all three methylation panels showed comparable sensitivity ranging from 68% (13/19) to 95% (18/19). Specificity of SOX1/ZSCAN1 panel (84%, 167/200) was considerably higher compared to ANKRD18CP/C13orf18/JAM3 (68%, 136/200, p = 2 × 10
Identifiants
pubmed: 30259973
doi: 10.1002/ijc.31897
pmc: PMC6587981
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
746-754Informations de copyright
© 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
J Clin Pathol. 2002 Apr;55(4):244-65
pubmed: 11919208
Leukemia. 2003 Dec;17(12):2257-317
pubmed: 14671650
Lancet. 2004 Jul 17-23;364(9430):249-56
pubmed: 15262102
Int J Cancer. 2005 Aug 10;116(1):122-9
pubmed: 15751045
Int J Cancer. 2006 Sep 1;119(5):1095-101
pubmed: 16586444
Int J Cancer. 2006 Oct 15;119(8):1908-14
pubmed: 16736496
Obstet Gynecol. 2008 Jan;111(1):167-77
pubmed: 18165406
Cancer Res. 2008 Apr 15;68(8):2661-70
pubmed: 18413733
BMJ. 2008 Oct 13;337:a1754
pubmed: 18852164
BMC Med Genomics. 2008 Nov 24;1:57
pubmed: 19025626
Int J Cancer. 2010 May 1;126(9):2175-81
pubmed: 19739071
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3000-7
pubmed: 19843677
J Clin Microbiol. 2011 May;49(5):1721-9
pubmed: 21430098
Int J Cancer. 2012 Apr 15;130(8):1861-9
pubmed: 21796628
Lancet Oncol. 2012 Jan;13(1):78-88
pubmed: 22177579
Int J Cancer. 2013 Sep 15;133(6):1293-9
pubmed: 23456988
J Clin Invest. 2014 Jan;124(1):24-9
pubmed: 24382386
Lancet Oncol. 2014 Mar;15(3):315-22
pubmed: 24529697
PLoS One. 2014 Mar 19;9(3):e91905
pubmed: 24647315
Int J Cancer. 2015 Feb 1;136(3):646-55
pubmed: 24923998
J Clin Pathol. 2014 Dec;67(12):1067-71
pubmed: 25281766
J Clin Microbiol. 2015 Jan;53(1):52-9
pubmed: 25339396
J Natl Cancer Inst. 2015 Jan 07;107(2):null
pubmed: 25568167
Epigenetics. 2015;10(1):73-81
pubmed: 25580631
Expert Rev Mol Diagn. 2015 Apr;15(4):527-46
pubmed: 25703310
Clin Microbiol Infect. 2015 Sep;21(9):817-26
pubmed: 25936581
Cancer Cytopathol. 2015 Dec;123(12):745-54
pubmed: 26230283
Int J Cancer. 2016 Feb 15;138(4):992-1002
pubmed: 26317579
J Natl Cancer Inst. 2015 Sep 15;107(12):djv257
pubmed: 26376685
J Clin Virol. 2016 Mar;76 Suppl 1:S49-S55
pubmed: 26643050
J Clin Virol. 2016 Mar;76 Suppl 1:S29-S39
pubmed: 26643051
Clin Epigenetics. 2016 Mar 09;8:29
pubmed: 26962367
Cancer Res. 2016 Jun 15;76(12):3446-50
pubmed: 27256564
Expert Rev Mol Diagn. 2016 Sep;16(9):961-74
pubmed: 27459506
Am J Clin Pathol. 2016 Sep;146(3):391-8
pubmed: 27543984
Expert Rev Anticancer Ther. 2016 Oct;16(10):1073-85
pubmed: 27598683
Oncotarget. 2016 Dec 6;7(49):80735-80750
pubmed: 27738327
Expert Rev Mol Diagn. 2017 Apr;17(4):379-391
pubmed: 28277144
Int J Cancer. 2018 Aug 15;143(4):735-745
pubmed: 29341110
Br J Radiol. 1997 Apr;70(832):360-6
pubmed: 9166071
Cancer Causes Control. 1997 Sep;8(5):755-63
pubmed: 9328198